Remove 2022 Remove Communication Remove Packaging
article thumbnail

Sustainable pharma packaging: breaking down the barriers to adoption

European Pharmaceutical Review

For most consumers, product packaging represents their first impression of a brand and its sustainability credentials. But how is this push shaping the pharma packaging market and what are the key changes we can expect to see? For many, aesthetic appeal and user experience top the list of priorities when it comes to packaging design.

article thumbnail

2022 spells change for EU pharmaceutical legislation

European Pharmaceutical Review

2022 is probably the biggest year in EU pharmaceutical law that I have seen in 30 years. 2022 is undeniably a critical year for change in the pharmaceutical industry: for the first time in several decades, the European Union (EU)’s pharmaceutical legislation is up for review. Key areas of potential legislative change. Future outlook.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Disrupted medical conferences: 2022 and beyond

pharmaphorum

Moreover, no attendee data was available for physical symposia, whereas all virtual symposia packages provided full attendee metrics analyses. Since then, many societies have indeed made discernible progress towards digital transformation of their events and communications practices. Expectations for 2022 and beyond.

article thumbnail

EU antibiotic shortages being monitored by MSSG

European Pharmaceutical Review

Monitoring medicine shortages Since November 2022, MSSG and its working party, the Medicines Shortages Single Point of Contact (SPOC) working party, have been closely monitoring the EU antibiotic shortages. Manufacturing delays and production capacity issues have led to supply problems affecting the majority of Member States.

article thumbnail

Enforcement Update: OPDP Issues Untitled Letter

Eye on FDA

We are four months into the year, and this week OPDP has issued its fourth regulatory action letter of 2022. In fact, over the past two years, the office issued only a total of 6 letters which means 2022 is going at a heightened clip. The Context. There are a couple of things of note.

article thumbnail

New IFPMA and EFPIA guidance on use of social media by the pharmaceutical industry

pharmaphorum

The overarching principle set out in Codes of Practice, and in particular the Principles for the use of digital channels in the EFPIA Code , is that the legislation and Codes of Practice apply equally to communications by companies on social media and digital channels.

article thumbnail

AI in pharmaceutical development: hype or panacea?

European Pharmaceutical Review

AI-based optic systems, for example, can enhance defect screening in manufacturing by scanning for packaging defects. 2022; 45(5): 429-438. Nature Communications. AI is playing an increasing role in sustainable development 15 and green chemistry by optimizing chemical processes to minimize environmental impact. Drug Discov.